Drug
Siplizumab
Siplizumab is a pharmaceutical drug with 7 clinical trials. Currently 4 active trials ongoing. Historical success rate of 33.3%.
Total Trials
7
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
4(57%)
Results Posted
300%(3 trials)
Terminated
2(29%)
Phase Distribution
Ph early_phase_1
1
14%
Ph phase_1
5
71%
Ph phase_2
1
14%
Phase Distribution
6
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
1(14.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
4
trials recruiting
Total Trials
7
all time
Status Distribution
Active(4)
Completed(1)
Terminated(2)
Detailed Status
Recruiting3
Terminated2
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
7
Active
4
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (14.3%)
Phase 15 (71.4%)
Phase 21 (14.3%)
Trials by Status
active_not_recruiting114%
recruiting343%
completed114%
terminated229%
Recent Activity
4 active trials
Showing 5 of 7
terminatedphase_1
Siplizumab in T1DM
NCT05574335
recruitingphase_2
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
NCT07508787
terminatedphase_1
Siplizumab for Sickle Cell Disease Transplant
NCT06078696
recruitingearly_phase_1
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
NCT06326476
active_not_recruitingphase_1
Delayed Tolerance Through Mixed Chimerism
NCT05900401
Clinical Trials (7)
Showing 7 of 7 trials
NCT05574335Phase 1
Siplizumab in T1DM
NCT07508787Phase 2
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
NCT06078696Phase 1
Siplizumab for Sickle Cell Disease Transplant
NCT06326476Early Phase 1
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
NCT05900401Phase 1
Delayed Tolerance Through Mixed Chimerism
NCT06455280Phase 1
A Study of SIPLIZUMAB in AILD and LT Patients
NCT01445535Phase 1
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7